Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

VBI Vaccines Inc. (VBIV)

0.9171   -0.046 (-4.77%) 06-26 22:20
Open: 0.963 Pre. Close: 0.963
High: 1.02 Low: 0.9101
Volume: 7,042,631 Market Cap: 237(M)
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.02 - 1.03 1.03 - 1.03
Low: 0.9 - 0.9 0.9 - 0.91
Close: 0.91 - 0.92 0.92 - 0.92

Technical analysis

as of: 2022-06-24 4:43:59 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.21     One year: 1.41
Support: Support1: 0.79    Support2: 0.64
Resistance: Resistance1: 1.03    Resistance2: 1.21
Pivot: 0.8
Moving Average: MA(5): 0.83     MA(20): 0.83
MA(100): 1.28     MA(250): 2.21
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 69.5     %D(3): 52.9
RSI: RSI(14): 51.9
52-week: High: 3.8  Low: 0.64
Average Vol(K): 3-Month: 2,903 (K)  10-Days: 7,438 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VBIV ] has closed below upper band by 27.3%. Bollinger Bands are 19.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 22 Jun 2022
Is VBI Vaccines Inc (VBIV) Stock Worth a Buy Wednesday? - InvestorsObserver

Wed, 22 Jun 2022
VBI Vaccines (VBIV) Receives US FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma - StreetInsider.com

Fri, 17 Jun 2022
3 Biotech Penny Stocks That Climbed in After-Hours Trading - StreetInsider.com

Fri, 17 Jun 2022
VBI Vaccines (NASDAQ:VBIV) Share Price Passes Below 200 Day Moving Average of $1.61 - Defense World

Tue, 07 Jun 2022
VBI Vaccines to Participate in the Jefferies Healthcare Conference - Yahoo Finance

Tue, 07 Jun 2022
VBI Vaccines Inc. (NASDAQ:VBIV) Expected to Announce Quarterly Sales of $700,000.00 - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 257 (M)
% Held by Insiders 1.9148e+008 (%)
% Held by Institutions 0.5 (%)
Shares Short 17,390 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -6.62e+007
EPS Est Next Qtl -0.24
EPS Est This Year -0.89
EPS Est Next Year -1.01
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -10
Return on Assets (ttm) 781.6
Return on Equity (ttm) -20.3
Qtrly Rev. Growth 631000
Gross Profit (p.s.) -25.82
Sales Per Share -22.56
EBITDA (p.s.) -5.17347e+006
Qtrly Earnings Growth -0.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -40 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.05
Price to Cash Flow 2.89

Stock Dividends

Dividend 0
Forward Dividend 1.778e+007
Dividend Yield 0%
Dividend Pay Date 2012-12-27
Ex-Dividend Date 2012-02-04
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.